



### In This Issue...

2

Highlights of the 2002 CNS Annual Meeting in Philadelphia

2

Brain/CNS Committee Meets

5

Research Subcommittee Report

7

Membership Application

8

Officers of the AANS/CNS Section on Tumors

## Chairman's Message

James T. Rutka, MD, PhD



James T. Rutka, MD, PhD

The Executive Council of the AANS/CNS Section on Tumors met on the occasion of the AANS Annual Meeting in Chicago, and continued to implement plans and strategies to enhance services to members, provide up-to-date information regarding research and

clinical opportunities, and review ways in which the academic mandate are being carried out.

### Bylaws Updated

Andrew Sloan, MD, has completed the corrections to the Tumor Section Bylaws which have not been changed since 1997. A mail ballot is currently being conducted to ratify these changes.

### Committees Report Stable Membership, Foundation Support

Ron Warnick, MD, provided us with an update of our membership which is very stable at 680 members. A motion was made and passed to nominate several key individuals to the status of honorary membership in the Tumor Section. These individuals include Peter Burger, MD, Gregory Cairncross, MD, Edward Shaw, MD, Stuart Grossman, MD, Web Cavenee, MD, Xandra Breakefield, PhD, and William Dillon, MD.

Michael McDermott, MD, gave a report from the Awards Committee. Communications are now being sent regularly to our many award sponsors to ensure that they are kept apprised of the awardees at each meeting. We have indeed been fortunate to welcome several representatives from each of the awarding foundations to our annual meetings where they have been encouraged to take part in the awards presentation ceremonies.

For the CNS 2002 meeting in Philadelphia, Jeffery Bruce, MD, has organized an outstanding symposium on state-of-the-art treatment of patients with brain tumors. This will be followed by presentations of the Awards papers, and the open paper session.

Peter Dirks, MD, organized the well-attended Young Neurosurgeons Reception for the Tumor Section in Chicago. Current, prospective and resident members alike were welcomed by Executive Committee members.

The [Tumor Symposium] was extremely successful, and was considered by many to be the highlight of the AANS Annual Meeting in terms of neuro-oncology papers and reports.

### Tumor Symposium Highlights AANS Meeting

I would like to direct special thanks to Nalin Gupta, MD, who organized the Fifth Biennial Brain Tumor Symposium at the Sheraton Hotel and Towers April 11-12, 2002. The program was extremely successful, and was considered by many to be the highlight of the AANS Annual Meeting in terms of neuro-oncology papers and reports. Preliminary financial statements indicate a net profit of approximately \$10,000, which will be used to support the mandate of the Tumor Section in all of its activities.

The Executive Council of the Tumor Section made a decision to donate \$15,000 to the AANS/CNS Washington Committee this year to support its ongoing important activities.

Finally, over the next several months, members of the Executive Council will be actively engaged in drawing up criteria for the accreditation of neuro-oncology fellowships across North America. In this regard, the Tumor Section will be working closely with the Society of Neurological Surgeons whose mandate it is to approve fellowships in various subspecialty areas of neurosurgery.

# Highlights of the 2002 CNS Annual Meeting in Philadelphia

Check [www.neurosurgery.org](http://www.neurosurgery.org) for registration, updates, and additional information.

## Monday, Sept. 23, 2002

### Tumor Section I

2:30-5:30 PM

Moderators: *Anthony L. Asher, Russell R. Lonser*

Topics addressed will be the natural history, surgical management and adjuvant treatment of primary brain neoplasms and neoplasms of the skull base.

- |           |   |
|-----------|---|
| 2:30-3:30 | Open Papers 725-731, Preuss Award, Young Investigator Award |
| 4:00-4:40 | Oral Posters 37-49  |
| 4:40-5:30 | Open Papers 732-737   |

## Tuesday, Sept. 24, 2002

### Special Course II: Review of Neuro-Oncology

2:30-5:30 PM

Moderator: *Kevin J. Gibbons*

Course Director: *James T. Rutka*

This course will focus on recent advances in biology and treatment of pituitary tumors, as well as the rationale for management of low-grade gliomas and cerebral metastatic disease.



2:30-3:30

State-of-the-Art Treatment of Low-Grade Gliomas

*Mitchel S. Berger*

Pituitary Tumors: Lessons Learned

*William F. Chandler*

Surgery for Metastatic Disease

*Raymond Sawaya*

Advances in Skull Base Technique

*Ossama Al-Mefty*

Applications of Imaging to Neuro-Oncology

*Peter McL. Black*

Advances in Pediatric Neuro-Oncology Surgery

*James T. Rutka*

30-minute break

4:00-5:30

Open Papers 752-762

Mahaley Clinical Research Award

## Wednesday, Sept. 25, 2002

### Tumor Section III

2:30-5:30 PM

Moderators: *John Kestle, Austin Colohan*

This general interest session will focus on primary brain neoplasms and neoplasms of the skull base. New developments in neuro-oncology will be discussed.

2:30-3:30

Open Papers 844-850

4:00-4:40

Oral Posters 50-62

4:40-5:30

Open Papers 851-856

### Brain/CNS Committee to Hold Information Session

The Brain/CNS Organ Site Committee of the American College of Surgeons Oncology Group will host a reception and information session on Tuesday, Sept. 24, at 6 p.m. in Salon D of the Philadelphia Marriott, in conjunction with the Congress of Neurological Surgeons annual meeting. All interested neurosurgeons and physicians in related specialties are invited to attend.

The ACOSOG is one of 10 cooperative groups funded by the Cancer Therapy Evaluation Program of the National Cancer Institute and is the only cooperative group whose focus is the evaluation of surgical therapies in patients with solid organ malignancies.

The Brain/CNS Organ Site Committee develops concept ideas for prospective, multicenter clinical trials for the treatment of brain tumors and collaborates with the ACOSOG Coordinating Center in opening these trials for patient accrual.

This information session will provide an overview of ACOSOG and the Brain/CNS Organ Site Committee. The opportunity for membership in ACOSOG and participation in ACOSOG trials will be discussed in detail. Samuel Wells, MD, ACOSOG chair, Anthony Asher, MD, Brain/CNS Organ Site Committee chair, and Edward Laws, MD, past committee chair, will moderate the session. Other ACOSOG members will also contribute to the session.

The ACOSOG allows neurosurgeons to examine significant clinical questions about malignant brain tumors through the cooperative group mechanism. The Brain/CNS Organ Site Committee recently opened its first study, Z0300, a phase III randomized trial of the role of whole brain radiation therapy in addition to radiosurgery in the management of patients with one to three cerebral metastases.

For more information visit [www.acosog.org](http://www.acosog.org).

A multi-disciplinary approach to the treatment of cancer of the central nervous system

# Journal of Neuro-Oncology

Editor:

**Joseph M. Piepmeier**

*Yale University School of Medicine, New Haven, CT, USA*

Visit our website at...

**[www.wkap.nl/journals/neuro\\_oncology](http://www.wkap.nl/journals/neuro_oncology)**

*for up-to-date information on Indexing/Abstracting services,  
Editorial Board & your FREE (online) sample copy.*

The *Journal of Neuro-Oncology* is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The *Journal of Neuro-Oncology* does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan literally dozens of journals of cell biology, pathology, laboratory and clinical endeavours, *JNO* is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.

#### **SUBSCRIPTION INFORMATION**

**ISSN 0167-594X**

2002, Volumes 56-60 (15 issues)

**Paper OR Online Version:**

EUR 1397.00 / USD 1400.00

**Combined Paper AND Online Version:**

EUR 1676.40 / USD 1680.00

*Individuals may subscribe (paper version only)*

*at the reduced rate of EUR 669.00 / USD 670.00*

*By signing the order form, they declare that the subscription is for their own use and that it will not be put at the disposal of any library*

**Special rate for American Academy of Neurology and  
Joint Section on Tumors:**

USD 258.00;

**for European Association of Neuro-Oncology:**

EUR 258.50.

Also available  
electronically  
via  
**KluwerOnline**

**JOURNAL  
HIGHLIGHT**

**Special**

**Rate!**

for American  
Academy of  
Neurology and  
Joint Section on  
Tumors

**&**

for European  
Association of  
Neuro-  
Oncology

**Kluwer**  
academic  
publishers





# INTRODUCING:

The free electronic notification system from Kluwer academic publishers giving you a headstart on your research!

# Kluwer Alert

- Advance notification by E-mail: new publications / forthcoming journal tables of contents
- Your own personal registration and selection of interest areas (subject, journals, bookseries)
- Privacy secured!

Visit... [www.kluweralert.nl](http://www.kluweralert.nl)

For further information and assistance, please send a message to [KAP-listserv@wkap.nl](mailto:KAP-listserv@wkap.nl)

**Journal of Neuro-Oncology**  
2002, Volumes 56-60 (15 issues), ISSN 0167-594X

REF: D2303/NEION

## ORDER FORM



- Please enter a 2002 subscription, **Paper Version**, EUR 1397.00 / USD 1400.00, including postage & handling
- Please enter a 2002 subscription, **Online Version**, EUR 1397.00 / USD 1400.00
- Please enter a 2002 subscription, **Combined Paper & Online Version**, EUR 1676.40 / USD 1680.00, including postage & handling. (When ordering the **Online Version**, please use the Kluwer Online subscription form at [www.wkap.nl/kaphtml.htm/KOACCESS](http://www.wkap.nl/kaphtml.htm/KOACCESS))
- Please enter a 2002 subscription for individuals, (paper version only) at the reduced rate of EUR 669.00 / USD 670.00, incl. postage & handling. *By signing the order form, I declare that the subscription is for my own use and that it will not be put at the disposal of any library.*
- Please enter a 2002 subscription for **American Academy of Neurology and Joint Section on Tumors** members, (paper version only) at the reduced rate of USD 258.00, including postage & handling.
- Please enter a 2002 subscription for **European Association of Neuro-Oncology** members, (paper version only) at the reduced rate of EUR 258.50, including postage & handling.
- Please send "Instructions for Authors".
- Payment enclosed to the amount of . . . . .  Please send invoice  Please charge my credit card account

Card. no.:

CVC\*

Expiry Date: . . . . .

- Am. Ex.  Visa  Mastercard / Eurocard

\* see back of the creditcard: 3 digits following the cardnumber

Title: . . . . . Initials: . . . . . Surname: . . . . .  
 Organization: . . . . . Department: . . . . .  
 Address: . . . . .  
 Postal Code: . . . . . City: . . . . . Country: . . . . .  
 Telephone: . . . . . FAX: . . . . .  
 E-mail: . . . . . Date: . . . . .

European VAT Registration Number:

Signature: . . . . .

**PLEASE SEND YOUR ORDER TO:**

Customers in Europe, Africa, Asia and Australasia: **Kluwer academic publishers**  
 Order Dept., P.O. Box 322 • 3300 AH Dordrecht, The Netherlands  
 Fax: +31-78-6576474 • Tel.: +31-78-6576422 • E-mail: [orderdept@wkap.nl](mailto:orderdept@wkap.nl)

Customers in USA, Canada, Mexico and Latin America: **Kluwer academic publishers**  
 Order Dept., P.O. Box 358 • Accord Station, Hingham MA 02018-0358, U.S.A.  
 Fax (781)871-6528 • Tel. TOLL FREE 1-866-269-wkap • E-mail: [kluwer@wkap.com](mailto:kluwer@wkap.com)

Subscriptions are accepted on a prepaid basis only, and delivery will take place after receipt of payment. Subscriptions are entered on a calendar year basis (January - December), and expire with the last issue of the last volume listed. Subscriptions will be entered on 'standing order' basis. Renewal notices will be sent automatically. Requests for private subscriptions should be sent to the publishers. By signing this form, private subscribers are declaring that the subscription is for their personal use only. Payment will be accepted in any convertible currency. U.S. Dollar prices apply to deliveries in the Americas only. Please check the rate of exchange at your bank. Prices are subject to change without notice. All prices are exclusive of Value Added Tax (VAT). Customers in The Netherlands please add 6% VAT. Customers from other countries in the European Community please \* fill in the VAT number of your institute/ company in the appropriate space on the order form; or\* add 6% VAT to the total order amount (customers from the UK are not charged VAT).

# Research Subcommittee Report

By Linda M. Liau, MD, PhD

**A** goal of the Research Subcommittee of the AANS/CNS Section on Tumors is to highlight scientific and clinical research opportunities and funding mechanisms that may be of interest to the membership. Such opportunities are available at the national and state levels, as well as through private foundations and agencies. In order to better navigate through the various research issues that may be pertinent to the section, the following is a summary of the information gathered by the Research Subcommittee for the period from Jan. 1, 2002, to July 15, 2002.

## National Funding Opportunities

**National Institutes of Health.** In a March 28, 2002, Federal Register notice, the NIH proposed to change the Public Health Service Policy on Use of Laboratory Animals to permit institutions with PHS Animal Welfare Assurances to submit verification of Institutional Animal Care and Use Committee approval *after* peer review but before actual award. This proposal will allow researchers to submit grant proposals for animal research without having to get institutional animal research committee approvals unless the grant is funded.

The following are recent NIH requests for applications (RFAs) that may be of interest to the Tumor Section membership. Further details can be obtained at: <http://grants.nih.gov/grants/guide/rfa-files>.

- RFA-CA-03-013: Molecular Interactions Between Tumor Cells and Bone
- RFA-CA-03-011: Community Clinical Oncology Program
- RFA-CA-03-010: Comprehensive Minority Institution/Cancer Center Collaboration
- RFA-CA-03-007: Cancer Communications Research
- RFA-CA-03-001: Nutritional Modulation of Genetic Pathways to Cancer
- RFA-CA-02-011: Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis

**Department of Defense.** The U.S. Army is soliciting proposals for its Peer Reviewed Medical Research Program. The PRMRP was established to provide support for military health-related research. All proposals must address the military relevance of the proposed efforts. Proposals are being solicited in 25 topic areas, including traumatic brain injury and radiation protection to the brain. A total of \$50 million is available to fund this program in fiscal year 2002. Individual awards are no more than \$3 million, inclusive of direct and indirect costs, with a maximum performance period of four years.

In order to complete requirements for submission of a proposal to the PRMRP, a principal investigator must download and read the following two documents: [www-usamraa.army.mil/pages/Baa\\_Paa/baa\\_announcements](http://www-usamraa.army.mil/pages/Baa_Paa/baa_announcements) and [www-usamraa.army.mil/pages/Baa\\_Paa/baa\\_02\\_1.cfm](http://www-usamraa.army.mil/pages/Baa_Paa/baa_02_1.cfm).

For more information, contact Pat Evans at the U.S. Army Medical Research Acquisition Activity at (301) 619-7354 or [pat.evans@amedd.army.mil](mailto:pat.evans@amedd.army.mil).

The U.S. Army Medical Research and Material Command is soliciting applications on Department of Defense tuberous sclerosis research. The Tuberous Sclerosis Complex Research Program (TSCRCP) is being established in fiscal year 2002 and will promote research directed toward a better understanding of the role and function of proteins produced by the TSC1 and TSC2 tumor suppressor genes.

Congress has appropriated \$1 million for the first TSCRCP competition. Funding can be requested for a maximum of \$425,000 for direct and indirect costs for a two- to three-year project period. Direct costs can cover salary, expenses including research supplies, and travel to scientific meetings (up to \$1,800 per year).

Eligible applicants must be independent investigators at the level of assistant professor or above.

Due dates:

- Sept. 4, 2002            Online letter of intent
- Sept. 12, 2002        Online proposal information form
- Sept. 18, 2002        Online full proposal

The full text of the fiscal year 2002 TSCRCP Program Announcement (with application instructions) can be downloaded from <http://cdmrp.org/proposals>.

## Biotechnology Industry

**Eppendorf AG and Science.** Eppendorf AG and *Science* magazine have initiated a new annual research prize of \$25,000. The prize acknowledges outstanding contributions to neurobiology research based on methods of molecular and cell biology. Young scientists who have received either an MD or PhD within the past 10 years are eligible. For more information, go to [www.eppendorf.com/award2002](http://www.eppendorf.com/award2002).

## Private Foundations

**American Institute for Cancer Research.** This institute is accepting applications for "investigator-initiated" grants to support research into the effects of diet and nutrition on cancer prevention and treatment. Principal investigators must hold a PhD or MD and the rank of assistant professor or higher. Individual awards are up to \$75,000 per year for two years, with competitive renewal, covering innovative rather than confirmatory research projects in dietary factors and the prevention or treatment of cancer. The grant application package can be downloaded from [www.aicr.org/grantapps.html](http://www.aicr.org/grantapps.html).

Due dates: Dec. 17, 2002, and July 1, 2003.

*Continued on page 6*

**Cancer Research Institute.** The CRI funds research at every level of inquiry aimed at furthering the development of immunological approaches to the diagnosis, treatment, and prevention of cancer. The following types of awards are now offered:

- *Postdoctoral Fellowship Program.* These fellowships are for training in cancer immunology. Applicants must have a doctoral degree and perform their research under a sponsor who holds a formal appointment at the host institution. Stipends are \$40,000 for the first year, \$42,000 for the second year, and \$44,000 for the third year. Due dates: April 1 and Oct. 1, 2002.
- *Investigator Award Program.* This program funds qualified scientists at the assistant professor level who are working in the field of tumor immunology. Applicants must have a doctoral degree and be a tenure-track assistant professor. Support is for \$50,000 per year for four years. Due date: March 1, 2002.
- *Clinical Investigation Program.* This grants program supports preclinical and clinical research in three specific areas: Cancer antigen identification for vaccine and antibody therapy; characterization of the immune response to cancer antigens; and fashioning of vaccine and antibody-based therapies for cancer. There is a three-year commitment of \$300,000 for preclinical research and \$450,000 for clinical trials grants. Due date: Feb. 1, 2002.

All application information and materials are available to download in PDF format from [www.cancerresearch.org](http://www.cancerresearch.org).

**Leukemia & Lymphoma Society.** In 2000, the Leukemia Society changed its name to Leukemia & Lymphoma Society to better reflect its commitment to find cures for lymphoma, including primary CNS lymphoma. The Society's Career Development Program provides salary support for fundamental and translational research.

Applicants should hold a PhD, MD, or equivalent degree and must be employed by an academic or non-profit institution.

The following LLS Career Development Awards are available:

- *Scholar*—Eligible applicants have been in an independent faculty-level appointment for no more than nine years as of Jan. 1, 2003.
- *Scholar in Clinical Research*—Eligible applicants have held an independent faculty-level appointment for no more than nine years as of Jan. 1, 2003. The proposed studies should translate new concepts in the basic sciences into clinical practice. Preference will be given to applicants whose research involves an early phase clinical trial of new or innovative applications.

Stipends are for a maximum of \$95,000, plus \$5,000 overhead per year for up to five years.

Due dates:

- Sept. 16, 2002—Mandatory electronic preliminary application via the Web site.
- Oct. 1, 2002—Full application receipt date via U.S. mail.

The Program Guidelines and Application Instructions may be accessed on the sponsor's Web site: [www.leukemia-lymphoma.org](http://www.leukemia-lymphoma.org). (Scroll down to select Research Grants; click on Grants Information then on Career Development Program.)

**Milheim Foundation for Cancer Research.** Grants are made to provide funds for research work in clinical or basic science toward the cure of cancer. The grant period is for one year, non-renewable, and ranges from \$10,000 to \$20,000. For more information, correspond with Liz Cameron or Vicki Lilly, Trust Associates, The Milheim Foundation, c/o U.S. Bank, 918 17th St., Denver, CO, 80202.

**James S. McDonnell Foundation.** This foundation supports research concentrating on the biology of brain cancer. The program supports novel research early in its development that will generate new knowledge leading to increased rates of survival and improved functional recovery for individuals with brain cancer. Suitable proposals are encouraged from junior faculty with strong neuroscience, genetics, molecular pathology, and tumor immunology backgrounds. Funding is up to a total of \$450,000 total costs for three years to no more than six years.

This funding mechanism employs a combination of online and print application materials. The required Web-based cover sheet is to be submitted electronically from the Web site, but must also be printed for use as the first two pages of each copy of the printed proposal. A completed paper application package (with the required amount of copies) accompanied by one electronic PDF file on disk or CD-ROM, must be submitted.

Due date: March 15, 2002. For more information, correspond with Cheryl Washington, Grants Manager, James S. McDonnell Foundation, 1034 S. Brentwood Blvd., Suite 1850, Saint Louis, MO, 63117.

**National Brain Tumor Foundation.** The NBTF funding cycle begins accepting grants in November and the deadline for applications is the following February. This year, new grants have been added with a focus on epidemiology and radiation treatments. There is also special funding for four grants focused specifically on oligodendroglioma research. For more information about the NBTF research program and an application, please visit the NBTF Web site at [www.braintumor.org](http://www.braintumor.org) and click on the Research icon at the bottom of the page.

## Moved? New E-mail?

Notify AANS, CNS and ABNS of changes to your contact information online. Go to [www.neurosurgery.org/directory](http://www.neurosurgery.org/directory), enter your name, click the "update your listing" button, and follow the instructions to quickly and easily update your listing for all three organizations at once.



American  
Association of  
Neurological  
Surgeons

# Application for Membership

## AANS/CNS Section on Tumors



**Eligibility:** Members of the AANS and/or CNS who have demonstrated a special interest in tumors of the nervous system.

### I. Biographical:

(A) Name: \_\_\_\_\_

(B) Home Address: \_\_\_\_\_

(C) Office Address: \_\_\_\_\_

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

(D) E-Mail (*Required*): \_\_\_\_\_

### II. Category of Membership Requested:

Active     Associate     International     Resident/Fellow     Adjunct

\* See [www.neurosurgery.org/Tumor/Memberinfo.html](http://www.neurosurgery.org/Tumor/Memberinfo.html) for Membership Category Descriptions.

### III. Membership, Certification and Practice:

(A) Are you certified by the American Board of Neurological Surgery?     Yes     No

(B) For Resident/Fellow Applications-Expected Training Completion Date (month/year) \_\_\_\_\_

(C) Are you a member of

1. American Association of Neurological Surgeons?     Yes     No

2. Congress of Neurological Surgeons?     Yes     No

(D) Are you currently involved in brain tumor research?  
Clinical-     Yes     No    Basic-     Yes     No

Suggestions on Section activities that would benefit you:

\_\_\_\_\_

\_\_\_\_\_  
Signature of Applicant

\_\_\_\_\_  
Date

**Please return completed application and curriculum vitae to:**

**Ronald E. Warnick, MD**  
**University of Cincinnati Medical Center**  
**222 Piedmont Ave. #3100**  
**Cincinnati, OH 45219**

**Phone: (513) 558-3179 Fax: (513) 558-0886 E-mail: [nsgymd@aol.com](mailto:nsgymd@aol.com)**

**AANS/CNS Section on Tumors**

5550 Meadowbrook Drive  
Rolling Meadows, Illinois 60008

FIRST CLASS  
U.S. POSTAGE  
PAID  
Des Plaines, IL  
Permit No. 329

**Officers of the AANS/CNS Joint Section on Tumors, 2001-2003**

**Chairman**

James T. Rutka, MD, PhD

**Past Chairman**

Joseph M. Piepmeier, MD

**Secretary-Treasurer**

Raymond Sawaya, MD

**Advisory Board**

Mark Rosenblum, MD  
Peter McL Black, MD  
Mark Bernstein, MD  
Edward R. Laws Jr., MD  
Jack Rock, MD  
Roberta Glick, MD  
Mitch Berger, MD  
Ossama Al-Mefty, MD

**Awards Committee**

Michael McDermott, MD

**Bylaws**

Andrew Sloan, MD

**Membership**

Ronald E. Warnick, MD

**Newsletter**

Gene H. Barnett, MD

**Membership Services**

Frederick J. Lang, MD

**Nominating**

Joseph M. Piepmeier, MD

**Research**

Linda Liau, MD

**Guidelines**

Jeffrey Olson, MD

**Program**

William T. Couldwell, MD  
(CNS San Diego 2001)  
William Broaddus, MD  
(AANS Chicago 2002)  
Jeffrey Bruce, MD  
(CNS Philadelphia 2002)  
Ab Guha, MD (AANS San Diego 2003)

**Education**

Nalin Gupta, MD  
(Satellite Symposium)  
Isabelle Germano, MD  
(*Neurosurgical Focus*)  
Antonio Chiocca, MD  
(*J Neuro-Oncology*)  
Anthony Asher, MD (*Select Review*)  
Corey Raffel, MD (Exam questions,  
Abstract Grading)  
Jeffrey Bruce, MD (Neuro-Oncology  
Update Course)  
Don O'Rourke, MD (*J Neuro-Oncology*)

**Young Neurosurgeons**

Peter Dirks, MD

**Washington Committee**

Lawrence Chin, MD

**International**

Jun Yoshida, MD  
Jorg Tonn, MD  
Shin Jung, MD  
Carlos Carlotti, MD